Compare AstraZeneca plc (AZN) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Cognizant Technology Solutions Corp — how do they compare? AstraZeneca plc trades at $156.8 (market cap $248.14B), while Cognizant Technology Solutions Corp trades at $58 (market cap $26.40B). The key difference: AstraZeneca plc is far larger — about 9.4× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| AZN | CTSH | |
|---|---|---|
Market Cap | $248.14B | $26.40B |
Sector | Health | Technology |
52-Week High | $209.48 | $86.70 |
52-Week Low | $147.06 | $38.73 |
Enterprise Value | $275.41B | $27.44B |
Dividend Yield | 2.01% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Cognizant (CTSH) trades at $58.19, down 0.21% today, with a bullish technical signal and strong cash flow. Recent Q2 2026 earnings missed estimates at $1.37 EPS, but revenue beat. The company maintains a solid net income margin of 10.26% and trades at a P/E of 12.58, below industry averages. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience amid AI-driven strategic shifts.
Outlook remains cautiously optimistic with upside potential from AI initiatives and financial services growth, though risks include client spending caution and competitive pressures. The stock's current valuation offers a margin of safety, but investors should monitor execution on AI integration and macroeconomic headwinds affecting IT spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
